NCT05290506View on ClinicalTrials.gov

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
PreDiabetesType 2 Diabetes
Interventions
DRUG

Dipeptidyl-Peptidase IV Inhibitors

All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12

Trial Locations (1)

81100

Hospital Sultan Ismail, Johor Bahru

All Listed Sponsors
lead

National University of Malaysia

OTHER

NCT05290506 - Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter